Compare FIZZ & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIZZ | LNTH |
|---|---|---|
| Founded | 1985 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 4.2B |
| IPO Year | 1991 | 2015 |
| Metric | FIZZ | LNTH |
|---|---|---|
| Price | $33.24 | $63.31 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $35.00 | ★ $74.17 |
| AVG Volume (30 Days) | 421.1K | ★ 1.1M |
| Earning Date | 12-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.66 | N/A |
| EPS | 1.98 | ★ 2.39 |
| Revenue | $1,202,396,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $2.80 | $0.01 |
| Revenue Next Year | $2.19 | $1.24 |
| P/E Ratio | ★ $16.79 | $26.45 |
| Revenue Growth | 0.46 | ★ 1.95 |
| 52 Week Low | $32.21 | $47.25 |
| 52 Week High | $50.51 | $111.29 |
| Indicator | FIZZ | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 71.16 |
| Support Level | $33.68 | $57.44 |
| Resistance Level | $35.88 | $59.30 |
| Average True Range (ATR) | 1.00 | 2.14 |
| MACD | 0.17 | 0.82 |
| Stochastic Oscillator | 17.13 | 91.35 |
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.